The World Health Organization prioritized three experimental Ebola treatments for the Bundibugyo strain: Mapp Biopharmaceutical’s MBP134, Regeneron’s maftivimab, and Gilead’s antiviral remdesivir, recommending these be tested in outbreak trials. Source: AdaDerana. Date: May 29, 2026.
